<section class="section property">
	<div class="container">
		<div class="row">
			<div class="col-md-4">
				<div class="property-media">
					<div class="property-icon">
						IP protections filed under <br> PCT/US2023/081775
					</div>
					<div class="property-info">
						*Altanine is considering new regulatory filings to broaden its sales, including orphan drug designation for Metformin in treating specific non-diabetic conditions, generic drug designation for Metformin gummies, and medical device designation for future Metformin-related applications.
					</div>
					<div class="property-img" data-paralax>
						<picture>
							<source srcset="../../img/home/property-img.png" type="image/png">
							<source srcset="../../img/home/property-img.webp" type="image/webp">
							<img src="../../img/home/property-img.png">
						</picture>
					</div>
				</div>
			</div>
			<div class="col-md-7 offset-md-1">
				<div class="property-desc">
					<p class="font-uppercase color-gradient section-subtitle">content</p>
					<h3 class="h3 section-title">Our Intellectual property</h3>
					<p>Altanine has an <b>exclusive, worldwide license </b> for the enteric coating for Metformin (including Metformin and Liraglutide combinations)</p>
					<ul>
						<li>
							Metformin & Liraglutide are generic drugs previously approved by the US Food & Drug Administration (FDA)
						</li>
						<li>
							Altanine can sell its products throughout the US using 503A and 503B compounding pharmacies to fill prescriptions
						</li>
						<li>
							Regulatory & IP have been vetted by GreenbergTraurig
						</li>
					</ul>
				</div>
			</div>
		</div>
	</div>
</section>